Get started
Author

Thomas Kelleher

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects
2003 · Robert L Murphy, Ian Sanne, et al. · AIDS · 195
Long-Term Efficacy and Safety of Atazanavir With Stavudine and Lamivudine in Patients Previously Treated With Nelfinavir or Atazanavir
2004 · Robin Wood, Praphan Phanuphak, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 103
Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease
2014 · Derek L.G. Hill, Adam J. Schwarz, et al. · Alzheimer s & Dementia · 97
Atazanavir—A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trials
2004 · Pedro E. Cahn, José M. Gatell, et al. · Journal of the International Association of Physicians in AIDS Care · 57
PDF
Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine
1999 · Thomas Kelleher, Anne Cross, et al. · Clinical Therapeutics · 32
Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine
1999 · Jane E. Mobley, Richard B. Pollard, et al. · AIDS · 24
Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies
2010 · Henri Roché, Pierfranco Conte, et al. · Breast Cancer Research and Treatment · 22
A bayes method for estimating the common mean of two normal populations
1996 · Thomas Kelleher · Communication in Statistics- Theory and Methods · 8
Autoimmune Pancreatitis in the Setting of Castleman Disease
2007 · Shishir K. Maithel, Wande Pratt, et al. · Pancreas · 7
The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection
1999 · Richard Elion, Sanjeev Kaul, et al. · Clinical Therapeutics · 4
Model-based assessment of benefit-risk profile of nivolumab (NIVO) flat dosing schedules (Q2W and Q4W) across multiple tumor types
2018 · X. Zhao, J. Shen, et al. · Annals of Oncology · 3
Missing Data Methods in HIV Clinical Trials: Regulatory Guidance And Alternative Approaches
2001 · Thomas Kelleher, Alexandra Thiry, et al. · Drug Information Journal · 3
Reply to M. Horiguchi et al
2018 · Dirk Schadendorf, Joel Jiang, et al. · Journal of Clinical Oncology · 1
Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors
2021 · Thomas Kelleher, Junliang Cai, et al. · Journal for ImmunoTherapy of Cancer
PDF
Coalition against major diseases: advancement of CSF and neuroimaging biomarkers as drug development tools to enable clinical trials in MCI
2013 · Dane Hill, Laurel Beckett, et al. · VUBIR (Vrije Universiteit Brussel)
O2‐11‐01: Prediction of disease progression in mild cognitive impairment from vMRI and concordance with cerebrospinal fluid biomarkers
2012 · Peng Yu, Adam Schwarz, et al. · Alzheimer s & Dementia
IC‐P‐041: Prediction of disease progression in mild cognitive impairment from vMRI and concordance with CSF biomarkers
2012 · Peng Yu, Adam Schwarz, et al. · Alzheimer s & Dementia
P2‐071: Biomarker Qualification in Alzheimer's Disease
2011 · Holly Soares, Denise Frank, et al. · Alzheimer s & Dementia
PDF
P3‐072: Assessing outcome measures for prodromal AD clinical trials: A retrospective analysis from the ADNI database
2009 · Howard H. Feldman, Thomas Blaettler, et al. · Alzheimer s & Dementia
Works count: 19
Citation count: 556
H-index: 8
I10-index: 7
Year
Topic
Type